November 11, 2019: Jo Viney, Pandion Co-Founder, President, and CSO, Featured in Endpoints News: "Twenty Extraordinary Women in Biopharma R&D Who Worked Their Way to the Top"

October 31, 2019: Pandion and Astellas Announce Collaboration to Deliver Pancreas-Targeted Immunomodulators

October 29, 2019: Jo Viney, Pandion Co-Founder, President, and CSO, Featured in Biotech2050's 3rd Podcast Episode

July 17, 2019: Pandion Therapeutics Appoints Rahul Kakkar, MD, as Chief Executive Officer

April 11, 2019: Twist Bioscience Announces Antibody Optimization Agreement with Pandion Therapeutics

December 19, 2018: Pandion Therapeutics Launches Type 1 Diabetes Focused Program with Investment from JDRF T1D Fund

October 2, 2018: FierceBiotech Names Pandion Therapeutics as One of its "Fierce 15" Biotech Companies of 2018

September 18, 2018: Just Biotherapeutics Announces Product Development and Manufacturing Agreement with Pandion Therapeutics

July 26, 2018: Pandion Therapeutics Announces Appointment of Nancy Stagliano to Its Board of Directors

April 16, 2018: Applied BioMath, LLC Announces Collaboration with Pandion Therapeutics for Semi-Mechanistic Pharmacokinetic and Target Occupancy Modeling in Autoimmune Disease

February 15, 2018: Pandion Announces Formation of Scientific Advisory Board

January 18, 2018: Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs for Autoimmune and Inflammatory Diseases

December 12, 2017Distributed Bio, Inc. and Pandion Therapeutics, Inc. Announce Multi-Target Collaboration